ArticleSouth Asian journal of cancer2013
Efficacy and safety of human papillomavirus vaccine for primary prevention of cervical cancer: A review of evidence from phase III trials and national programs.
Article in South Asian journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Human papillomavirus (HPV) genotype distribution in Malaysia: A systematic review.BMC infectious diseases · 2025Pooled it
- Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.The Cochrane database of systematic reviews · 2018Pooled it
- HPV vaccination in the WHO South-East Asia Region: A scoping review of uptake, implementation challenges, and pathways to acceleration.Human vaccines & immunotherapeutics · 2026Article
- Article
- Vaccination coverage against HPV in a national representative sample of schoolgirls aged 12-18 years in Greece and core knowledge factors in parents' decision to vaccinate their daughters.Journal of public health research · 2025Article
- Mechanisms Underlying the Therapeutic Effects ofInternational journal of genomics · 2025Article
- Knowledge, Perceptions and Attitudes Toward HPV Vaccination: A Survey on Parents of Girls Aged 11-18 Years Old in Greece.Frontiers in global women's health · 2022Article
- The Immunotherapy Landscape in Adrenocortical Cancer.Cancers · 2021Review
- Experience of Human Papillomavirus Vaccination Project in a Community Set Up-An Indian Study.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Knowledge and attitude regarding cervical cancer and its prevention among young female adults in Kuantan, Malaysia.Journal of education and health promotion · 2021Article
- Single-dose nonavalent HPV vaccine: Need of the hour.Nepal journal of epidemiology · 2020Article
- Application of Disease Etiology and Natural History to Prevention in Primary Health Care: A Discourse.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2020Review
- Prevalence of HPV Genotypes in South Europe: Comparisons between an Italian and a Turkish Unvaccinated Population.Journal of environmental and public health · 2019Article
- Efficacy of Nd:YAG laser therapy for the treatment of verrucae: a literature review.Lasers in medical science · 2017Review
- Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.BMC public health · 2017Article
- Article
- Factors Associated with HPV Vaccination among Cambodian American Teenagers.Public health nursing (Boston, Mass.) · 2016Article
- The most effective and promising population health strategies to advance human papillomavirus vaccination.Expert review of vaccines · 2016Review
- Safety of human papillomavirus vaccines: a review.Expert opinion on drug safety · 2015Review
- Human papillomavirus-16/18 AS04-adjuvanted vaccine (cervarix®): a guide to its two-dose schedule in girls aged 9-14 years in the EU.Paediatric drugs · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Human Papillomavirus (HPV) vaccines have been widely introduced in the national immunization programs in most of the medium and high income countries following endorsement from national and international advisory bodies. HPV vaccine is unique and its introduction is challenging in many ways - it is the first vaccine developed to prevent any cancer, the vaccine is gender specific, it targets adolescent females who are difficult to reach by any health intervention programs. It is not unusual for such a vaccine to face scepticism and reservations not only from lay public but also from professionals in spite of the clinical trial results convincingly and consistently proving their efficacy and safety. Over the last few years millions of doses of the HPV vaccine have been administered round the world and the efficacy and safety data have started coming from the real life programs. A comprehensive cervical cancer control program involving HPV vaccination of the adolescent girls and screening of the adult women has been proved to be the most cost-effective approach to reduce the burden of cervical cancer. The present article discusses the justification of HPV vaccination in the backdrop of natural history of cervical cancer, the mechanism of action of the vaccines, efficacy and safety data from phase III randomized controlled trials as well as from the national immunization programs of various countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.